Hemodialysis in Brazil: differences across geographic regions regarding demographics, laboratory parameters and drug prescription

ABSTRACT

Introduction:

Brazil has a vast territory divided into five geographic regions with important differences in sociodemographic indices. We aimed to present and compare socio-demographic characteristics, biochemical results, and drug prescription of patients on chronic hemodialysis (HD) treatment in the five geographic regions.

Methods:

We evaluated data from the Brazilian Dialysis Registry of all adult patients undergoing chronic HD in 2021. Variables included sociodemographic characteristics, serum levels of phosphate, calcium, and albumin, hemoglobin, urea reduction rate, and prescription of phosphate binders, erythropoietin, and intravenous iron. Data from the North and Northeast regions were combined into one group.

Results:

A total of 13,792 patients (57.9 ± 16.0 years old, 58.5% male, median HD vintage of 31 (11–66) months) from 73 dialysis centers were analyzed. Regional distribution was 59.5% in the Southeast; 21.7% in the South; 5.9% in the Midwest; and 12.9% in the North/Northeast. Sociodemographic features, biochemical results, and medication prescriptions differed across regions. The prevalence of elderly patients was lower in the Midwest and North/Northeast. The South region had the highest prevalence of hyperphosphatemia (41.2%) and urea reduction rate <65% (24.8%), while anemia and hypoalbuminemia were more prevalent in the Southeast, 32.7% and 11.6%, respectively.

Conclusion:

We found differences in socio-demographics, clinical features, and drug prescriptions across Brazilian geographic regions. Some findings reflect the socio-demographic diversity of the country, while others deserve further elucidation.

Keywords
Renal Dialysi; Epidemiology

Introdução:

O Brasil possui um vasto território dividido em cinco regiões geográficas com importantes diferenças nos índices sociodemográficos. Nosso objetivo foi apresentar e comparar características sociodemográficas, resultados bioquímicos e prescrição de medicamentos de pacientes em tratamento de hemodiálise crônica (HD) nas cinco regiões geográficas.

Métodos:

Avaliamos os dados do Registro Brasileiro de Diálise de todos os pacientes adultos submetidos à HD crônica em 2021. As variáveis incluíram características sociodemográficas, níveis séricos de fosfato, cálcio e albumina, hemoglobina, taxa de redução de ureia e prescrição de quelantes de fosfato, eritropoietina e ferro intravenoso. Os dados das regiões Norte e Nordeste foram combinados em um único grupo.

Resultados:

Foi analisado um total de 13.792 pacientes (57,9 ± 16,0 anos, 58,5% do sexo masculino, mediana de tempo de HD de 31 (11–66) meses) de 73 centros de diálise. A distribuição regional foi de 59,5% dos pacientes provenientes do Sudeste; 21,7% do Sul; 5,9% do Centro-Oeste; e 12,9% do Norte/Nordeste. As características sociodemográficas, os resultados bioquímicos e as prescrições de medicamentos diferiram entre as regiões. A prevalência de pacientes idosos foi menor nas regiões Centro-Oeste e Norte/Nordeste. A região Sul apresentou a maior prevalência de hiperfosfatemia (41,2%) e taxa de redução de ureia < 65% (24,8%), enquanto a anemia e a hipoalbuminemia foram mais prevalentes no Sudeste, 32,7% e 11,6%, respectivamente.

Conclusão:

Encontramos diferenças nos dados sociodemográficos, nas características clínicas e prescrições de medicamentos nas regiões geográficas brasileiras. Alguns achados refletem a diversidade sociodemográfica do país, enquanto outros demandam maiores esclarecimentos.

Descritores
Diálise Renal; Epidemiologia

Introduction

Brazil has a population of more than 213 million people and a land area of over 8.5 million km2 ¹. The vast Brazilian territory is divided into five geographic regions that differ in demographic, cultural, social, economic, and health aspects².

It was estimated that almost 150 thousand Brazilians were on chronic dialysis treatment in 2021, 94.2% of them on hemodialysis³. Significant regional differences in demographic, clinical, and outcomes were found in a large Brazilian cohort of peritoneal dialysis patients followed from 2004–2007⁴, but little is known about the current profile of people on HD in the different regions.

The identification of possible regional differences in socio-demographic and laboratory parameters among the growing number of patients on chronic HD can expand the understanding of possible barriers and regional characteristics related to HD treatment. Using data from a large Brazilian cohort of chronic dialysis, we presented and compared demographic characteristics, biochemical results, and drug prescription across geographical regions.

Methods

This is a retrospective analysis of data from the Brazilian Dialysis Registry (BDR), a non-probabilistic national electronic database of standardized clinical and epidemiological information (baseline and follow-up) of patients undergoing dialysis. Detailed methods for the BDR data collection have been published elsewhere⁵.

Patients from 73 dialysis centers were included in this analysis, corresponding to 9% of the total number of Brazilian centers (14% in the South, 9% in the Southeast and Midwest, 8% in the North, and 3% in the Northeast).

In this study, we evaluated data of all incident and prevalent adult patients (>18 years old) undergoing chronic HD in 2021. We excluded participants with less than two months of information in 2021 and patients on peritoneal dialysis. Data from the Southeast, South, and Midwest regions were presented separately; the ones from the North and Northeast regions were combined to keep the balance among the other regions due to their lower participation.

Study variables comprised demographics (gender, age, skin color, and education level), CKD etiology, dialysis vintage, funding, and biochemical parameters. For the monthly collected variables such as serum phosphate (P), total serum calcium (Ca), hemoglobin (Hb), and dialysis urea reduction rate (URR), numbers represent the mean of at least three results of the year; for serum albumin, which was collected once every three months, a minimum of two results were computed. Participants were calssified as having hyperphosphatemia (P > 5.5 mg/dL), hypercalcemia (Ca > 10.5 mg/dL), anemia (Hb < 10 g/dL), inadequate dialysis (URR < 65%), and hypoalbuminemia (Alb < 3.5 g/dL) based on previously recommended cut-off values⁶–⁸.

We analyzed the frequency with which physicians prescribed erythropoietin, intravenous (IV) iron, sevelamer, and calcium carbonate. Drug prescriptions were expressed as a percent of total months with information. For example, for a participant with 10 months of available information and four months of prescription, drug prescription was 40%. A minimum of 6 months of information in the database was required to calculate drug prescription.

Statistical Analysis

Variables are reported as means and standard deviations, median and interquartile, or percentages, as appropriate. Means were compared using one-way ANOVA complemented by the Tukey test or Kruskall-Wallis ANOVA complemented by Dunn test. Differences between categorical variables were assessed by the chi-square test. We used the Southeast region as reference.

The SPSS Statistics for Windows version 21.0 was used to analyze the data. P-values <0.05 were considered significant.

Results

A total of 18,538 dialysis patients were identified in 2021, and 13,792 met the inclusion criteria (Figure 1).

Figure 1.
Flowchart of study participants.

The general characteristics of our sample and comparisons across the different geographic regions are shown in Table 1. Patients from the Southeast comprised almost 60% of our sample. Almost half were elderly. Most of the included participants were non-white males with more than eight years of formal education. Hypertension was the most prevalent CKD etiology. The median dialysis vintage was 2.5 years, and the main source of dialysis funding for participants was public (67.5%). Except for gender, all other variables had a different distribution across regions. Patients from all other regions were younger than those from the Southeast. Compared to the Southeast, participants from the South and Midwest had lower educational level. In addition, the South and North/Northeast had a higher prevalence of diabetes and of participants with publicly funded HD treatment than the Southeast.

Table 1.
General characteristics of the total sample and across geographic regions

	Total N = 13,792	Southeast N = 8,207 (59.5%)	South N = 2,990 (21.7%)	Midwest N = 820 (5.9%)	North/Northeast N = 1,775 (12.9%)
Gender male, N (%)	8,072 (58.5)	4,789 (58.4)	1,725 (57.7)	500 (61.0)	1,061 (59.8)
Age, years Percent > 60 years old	57.9 ± 16.0a 48.9%	58.6 ± 16.3 49.9%	57.5 ± 15.3** 49.1%	56.4 ± 15.3** 44.3%**	56.1 ± 15.9** 45.7%**
Dialysis vintage, months	31 (11–66)b	34 (12–68)	27 (8–63)**	34 (11–67)	28 (10–61)**
White skin color, N (%)	6,596 (47.8)	3,596 (43.5)	2,322 (77.7)**	317 (38.7)**	391 (22.0)**
≥8 years at school, N (%)	10,792 (73.6)	6,195 (75.5)	2,007 (67.1)*	588 (71.7)*	1,355 (76.3)
CKD Etiology, N (%) Hypertension Diabetes Glomerulonephritis Polycystic kidney disease Other Unknown	3,057 (27.1) 2,684 (23.7) 1,135 (10.0) 566 (5.0) 3,160 (27.9) 723 (6.4)	2,077 (29.4) 1,438 (20.4) 596 (8.4) 344 (4.9) 2,260 (32.0) 343 (4.9	456 (20.7)** 641 (29.1)** 291 (13.2)** 144 (6.5)** 411 (18.7)** 256 (11.6)**	152 (22.2)** 135 (19.7) 113 (16.5)** 38 (5.5) 231 (33.7) 17 (2.5)**	382 (27.4) 470 (33.8)** 137 (9.7) 40 (2.9) 258 (18.5)** 107 (7.7)**
Public funding, N(%)	9,282 (67.5)	5,050 (61.7)	2,561 (87.7)**	524 (64.5)	1,147 (64.8)*
Incidents, N(%)	1,396 (10.1)	614 (7.5)	443 (14.8)**	111 (13.5)**	228 (12.8)**

• ^aMean ± S.D.; ^bMedian (range); *P < 0.05 vs. Southeast region; **P < 0.01 vs. Southeast region.

Regarding biochemical parameters, significant differences were found between the other regions and the Southeast for every analyzed parameter (Table 2). The prevalence rate of hyperphosphatemia, for instance, was 2.0 and 1.4 times higher in the South and North/Northeast regions, respectively. Hypercalcemia in the South and Midwest regions was 1.8 and 2.1 times higher, respectively. The Southeast had the highest prevalence rate of anemia (32.7%), with the Midwest having close to half of that. The Southeast had the lowest prevalence rate of inadequate URR (<65%) (13.9%), with all other regions having a significantly higher rate. Regarding hypoalbuminemia, the studied population had a prevalence rate of 10.9%, with the Midwest (9.2%) and North/Northeast (7.0%) showing a lower prevalence rate than the Southeast (11.6%).

Table 2.
Biochemical results of the total sample and across geographic regions

	N	Data availability (Mo.)	Total	Southeast	South	Midwest	North/ Northeast
Serum phosphate, mg/dL >5.5 mg/dL (%)	12,038	8 (5–10)b	4.8 ± 1.3a 26.9	4.7 ± 1.2 21.9	5.3 ± 1.4** 41.2**	4.6 ± 1.2 20.2	4.9 ± 1.3** 29.7**
Serum calcium, mg/dL >10.5 mg/dL (%)	11,420	9 (5–10)	8.7 ± 0.7 1.3	8.5 ± 0.7 1.0	8.9 ± 0.7** 1.8**	8.9 ± 0.7** 2.1*	8.8 ± 0.7** 1.4
Hemoglobin, g/dL <10 g/dL (%)	12,119	9 (5–10)	10.5 ± 1.6 31.5	10.5 ± 1.6 32.7	10.5 ± 1.5 30.6	10.9 ± 1.3** 20.8**	10.6 ± 1.6 32.5
Urea reduction rate, % <65% (%)	11,402	9 (5–10)	71 ± 8 18.1	72 ± 8 13.9	69 ± 8** 24.8**	72 ± 10 22.8*	69 ± 8** 22.9**
Serum albumin, g/dL <3.5 g/dL (%)	9,842	3 (2–4)	3.8 ± 0.4 10.9	3.8 ± 0.3 11.6	3.9 ± 0.4** 11.3	3.8 ± 0.3 9.2*	4.0 ± 0.4** 7.0**

• Mo.: months; ^aMean ± S.D.; ^bMedian (range); *P < 0.05 vs. Southeast region; **P < 0.01 vs. Southeast region.

The prescription of phosphate binders is showed in Figure 2. In the whole population, sevelamer was prescribed for 0-50% and 51-100% of the time to 67.9% and 32.1% of the participants, respectively. Sevelamer was significantly less used by patients from the Midwest than in those from the Southeast. For calcium carbonate, all regions had significantly different prescription frequency compared to the Southeast, where 22.1% were supplemented for more than 50% of time. In the South, Midwest, and North/Northeast, corresponding numbers were 62.0%, 8.8%, and 16.0%, respectively.

Figure 2.
Percent of participants receiving phosphate binders in the different geographical regions: calcium carbonate (Panel A); sevelamer (Panel B). N = 9,375; median number of months with available data: 10 (9–11); *P < 0.01 vs. Southeast region.

Erythropoietin and IV iron prescriptions in people with anemia are shown in Figure 3. The prevalence of patients receiving erythropoietin for more than half of the assessed time was 76.6% in the Southeast region; corresponding figures for the South and North/Northeast were 53.2% and 97.5%, respectively. For IV iron prescription, no significant difference was observed across regions. The percent of participants receiving IV iron for less than 50% of the time in the study population was 38.1% and for more than 50% of the time, 61.9%.

Figure 3.
Percent of participants receiving erythropoietin (Panel A) and intravascular iron (Panel B) in the different geographical regions. N = 2,682; median number of months with available data: 10 (8–10); *P < 0.01 vs Southeast region.

Discussion

In this retrospective analysis of a large Brazilian chronic HD population, we found differences in demographics, several laboratory parameters and selected medication prescriptions across Brazilian geographic regions.

The geographic distribution of our sample differed from that of the Brazilian general population (Southeast: 59.5 vs. 42%; South: 21.7 vs. 14%; Midwest: 5.9 vs. 7% North/Northeast: 12.9 vs. 36%, respectively). The over-representation of patients from the South and Southeast is due to their higher voluntary participation in the registry.

Patients from the Southeast and South had a higher percentage of elderly (>60 years), corroborating results from a previous large cohort of Brazilian PD patients⁴ and current national demographics⁹. Compared with national population data, included patients had a higher prevalence of whites (47.8 vs. 42.7%)¹⁰ and a higher percentage of people with complete elementary school (≥ 8 years of schooling; 73.6 vs. 61.4%)¹¹. Both results can be attributed to the over-representation of participants from the Southeast and South. These two geographic regions have a higher predominance of European colonization and better social and economic development².

Hypertension and diabetes were the main CKD etiologies of participants, although in lower prevalence rates than those reported in the 2021 Brazilian Dialysis Survey (BDS) (27.1 and 23.7% versus 32 and 30%, respectively)³. We can not rule out misclassification of the primary renal diagnosis informed in the BDR as it is generally based on the patient’s history and not confirmed by renal biopsy. This uncertainty is also commonly observed in other registries (USRDS).

The percentage of patients whose dialysis was funded by private health insurance was higher in our sample than in the 2021 BDS, which comprised data from approximately 30% of all people undergoing chronic dialysis in our country (32.5 vs. 18.2%, respectively)³.

Surprisingly, comparisons of demographic characteristics across regions show that participants from the South had a lower educational level than those from similar and less developed regions. The most likely explanation is the higher prevalence of patients with public dialysis funding in our sample, reflecting the lower social and economic levels of the patients. Based on comparisons with the 2021 BDS, study participants with private health insurance are over-represented in all regions except the South.

Participants from the South had the highest mean serum phosphate levels and the highest prevalence of hyperphosphatemia, which was 50 to 100% higher than in other regions. Dietary habits in the South are a potential factor in this regard. A small study that compared the frequency of intake of 33 phosphate-containing foods between HD patients from the South and the North found that patients from the South consumed 14 of these foods more frequently, including dairy products and processed meat¹², in line with the results of the national dietary survey¹³.

One of the strategies used to treat hyperphosphatemia is the use of oral phosphate binders¹⁴. Although we did not observe a higher frequency of prescription of sevelamer in patients from the South, this was true for calcium carbonate. Sixty-two percent of participants used it over 50% of the time, against 9 to 22% of participants in the other regions.

The prevalence of anemia in the total sample (31.5%) was slightly higher than that reported in previous publications of the BDS (27–30%)¹⁵ and slightly lower than a previous analysis from the same registry (33.1%)⁵. The prevalence rates found were similar across regions, except for the Midwest, where 20.8% of patients had low hemoglobin levels (<10 g/dL). Regarding medications, almost all participants from the North/Northeast (97%) with anemia had a prescription of erythropoietin for more than 50% of the assessed time, a number markedly higher than the 53% of the South, 77% of the Southeast, and 71% of the Midwest. The public health system provides erythropoietin free of charge to patients, and its dispensing is subject to local regulations. It is known that in some states patients are actually given the prescribed dose, while in other states, patients receive less medication than indicated due to government restrictions and bureaucracy. We wonder if this fact may have impacted drug prescription. No differences were observed in the use of IV iron across regions. There are several factors involved in the prescription of EPO and IV iron and in anemia assessment that are beyond the scope and require further investigation.

Concerning dialysis adequacy, the region with the best results was the Southeast, with only 13.9% of patients with inadequate post-dialysis URR, whereas the figures for the other states were between 23–25%. Of note, these prevalence rates are far better than the 38.5% of inadequate URR found in a report of this registry comprising 24,930 prevalent and incident patients between 2011–2017⁵. In the last reports of the BDS, Kt/V <1.2 was the indicator used for dialysis inadequacy and was found in 18-20% from 2016 to 2019¹⁵. The URR, although not as precise as the Kt/V, has long been accepted in the international literature as a useful and practical measure for assessing dialysis adequacy, particularly in large databases.

Dialysis adequacy is influenced by several factors, including dialysis-related parameters (session frequency and duration, type of HD membrane) and patient characteristics (residual renal function, body size, fluid overload, etc.)⁷. Further studies addressing this aspect are necessary to explain this finding.

The overall prevalence of hypoalbuminemia (10.6%) was lower than in the last BDS report (14–16%)¹⁵. Midwest and North/Northeast patients were less likely to have low serum albumin levels compared with Southeastern participants. Serum albumin is influenced by inflammation, comorbidity, liver failure, nutritional status, volume expansion, and urinary or dialysate protein losses¹⁶. The lack of investigation of these parameters prevents us from finding plausible explanations for these differences.

As study limitations, we highlight the low participation of dialysis centers from the North/Northeast, the lack of more detailed information about comorbidities and some clinical and laboratory parameters such as serum calcium adjustment for serum albumin, and EPO and iron use indications. Also, the study has the hurdles inherent to the retrospective study design. Since the data collection took place in 2021, our findings may have been influenced by the COVID-19 pandemic, although we do not have information about medication shortage in this period. As strengths, we should mention the large number of participants from accross the country and the report of multiple biochemical analyses and medication prescriptions. In addition, this report provides useful information for people and agencies involved in renal replacement therapy, such as industry, government, policy makers, and health professionals, enabling regional comparisons and care planning.

In conclusion, we found differences in demographics, clinical-laboratory parameters, and drug prescriptions of chronic dialysis patients across Brazilian geographic regions. Highlighting these inequalities is pivotal, particularly in a large country like Brazil. Some of these differences reflect the socio-demographic diversity of our country, while others deserve further elucidation.

Acknowledgements

Brazilian Dialysis Register Investigators: Beatriz Veneza; Carlos Eduardo Comin; Yoshimi Watanabe; João Carlos Biernat; Patrícia Sigolo Teixeira; Sérgio Gardano Elias Bucharles; Elzo Ribeiro Junior; Geraldo Antunes Córdova; Marcelo Augusto Gonçalves; Gisele Fernandes Furtado; Roberto Eduardo Salon; Milene Cristina Devito Guilhem; Hotone Dallacosta; Marco Túlio; Renato Jorge Palmeira de Medeiros; Elisa de Albuquerque Sampaio; Jorge Luiz Zanette Ramos; Gelson Antonio dos Santos; Orlando Belin Junior; Neyde Vinhacico Pontes; Ana Cristina Matos; Ciro Tavares Costa; Luiz Felipe B. de Figueiredo; Sílvia Corradi Faria de Medeiros; Cyro Nogueira Fraga Moreira Filho; Homero Neto de Cunha e Agra Sul; Wagner Santa Catharina; Sandra Teresa de Souza Neiva Coelho; Manif Curi Jorge; Mendell Douglas Lemos; Rodrigo Motta Pereira; Maziael Moraes; Helio Enzio Galvão; Rosilene Coelho; Ronaldo Luiz Ennes Allão; Luiz Claudio Albuquerque Gonçalves; Jair Batista Miguel; Rosa Malta; Jorge Arnaldo Valente de Menezes; Raimundo Martins Neto; Maria Emilia Duarte Diniz; Sinaria Amaral Ojeda; Flávio José Dutra de Moura; Luciana Fernandes Serpa; Tania Duran Sobral; Marcos Ari Mura; Ana Cláudia Vaz do Amaral Barbosa; Marcos Gevert ; Nelson José; Zita Maria Leme; Márcio Azevedo Moraes; Fabia Fernandez; Natasha Silva Constancio; Roberto Benvenutti; Ian Robert Rehfeldt; Julio Cesar; Marilia Bahiense Oliveira; Flavio Menezes de Paula; Nilsa do Rosario Martins; Denise de Melo; Ismar Caetano Monteiro Junior; Jeronimo Ruiz Centeno; Luiz Antonio C. Pais; Consuelo Veloso de Carvalho; Aparecida Paula Gondim Visoná; Maria Goretti Polito; Januário Gonçalves Roberto; Glória Maria Furatado dos Reis; João Damásio Sottero Simões; Tânia Brandão; Fernando Saldanha Thomé; Ana Lydia Cabeça; Marcos Scheidemantel; Márcia Beatriz Hexsel Abichequer; Eli Nogueira da Silva; Silvana Mourão Oliveira; Renata Lamego Starling; José Miguel Viscarra Obregón; Marcelo Freire Ruas; Antonio Alberto Coelho de Brito; Ana Bela de Barros Palazzo; Mario Ernesto Rodrigues; Rafael Cruzeiro Siqueira; Aluizio da Costa e Silva; Nilso Moreira; Maria de Fátima Alvarenga; João Carvalho Filho; André Luiz Marassi; Rodrigo Braz; Cristiano Viana da Silva; Fernanda Salomão Gorayeb Polacchini; Henrique Luiz Carrascossi; Leandro Júnior Lucca; Gelzie Sorrentino Ennes.

References

• ^1.
  Instituto Brasileiro de Geografia e Estatística. Cidades e Estados [Internet]. Rio de Janeiro: IBGE; 2022. [cited 2022 Oct 17]. Available from: https://www.ibge.gov.br/cidades-e-estados
  » https://www.ibge.gov.br/cidades-e-estados
• ^2.
  Instituto Brasileiro de Geografia e Estatística. Síntese de Indicadores sociais: uma análise das condições de vida da população brasileira 2021. Rio de Janeiro: IBGE; 2021.
• ^3.
  Nerbass FB, Lima H do N, Thomé FS, Vieira Neto OM, Lugon JR, Sesso R. Brazilian Dialysis Survey 2021. Brazilian J Nephrol 2022;44(3):349–357. doi:10.1590/2175-8239-jbn-2021-0198
  » https://doi.org/10.1590/2175-8239-jbn-2021-0198
• ^4.
  Maria N, Alberto A, Pecoits-filho R. Geografia da diálise peritoneal no Brasil : análise de uma coorte de 5.819 pacientes (BRAZPD). J Bras Nefrol. 2010;32(3):268–74. doi: http://dx.doi.org/10.1590/S0101-28002010000300008. PubMed PMID: 21103690.
  » https://doi.org/10.1590/S0101-28002010000300008
• ^5.
  Lugon JR, Gordan PA, Thomé FS, Lopes AA, Watanabe YJA, Tzanno C, et al. A web-based platform to collect data from ESRD patients undergoing dialysis: methods and preliminary results from the Brazilian Dialysis Registry. Int J Nephrol. 2018;2018:9894754. doi: http://dx.doi.org/10.1155/2018/9894754. PubMed PMID: 29692934.
  » https://doi.org/10.1155/2018/9894754
• ^6.
  Moe SM, Drueke TB. Group for the KW. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention and treatment of chronic kidney disease mineral and bone disorder (CKD-MBD). Kidney Int. 2017;76(Suppl 113):S1–128. doi: http://dx.doi.org/10.1038/ki.2009.188
  » https://doi.org/10.1038/ki.2009.188
• ^7.
  Daugirdas JT, Depner TA, Inrig J, Mehrotra R, Rocco MV, Suri RS, et al. KDOQI Clinical Practice Guideline for Hemodialysis Adequacy: 2015 Update. Am J Kidney Dis. 2015;66(5):884–930. doi: http://dx.doi.org/10.1053/j.ajkd.2015.07.015. PubMed PMID: 26498416.
  » https://doi.org/10.1053/j.ajkd.2015.07.015
• ^8.
  Brasil. Ministério da Saúde. Secretaria de Atenção à Saúde. Portaria No 365, de 15 de fevereiro de 2017. Aprova o Protocolo Clínico e Diretrizes Terapêuticas Anemia na Doença Renal Crônica. Diário Oficial da União; Brasília; 2017.
• ^9.
  Instituto Brasileiro de Geografia e Estatística. PNAD Contínua. População cresce, mas número de pessoas com menos de 30 anos cai 5,4% de 2012 a 2021 [Internet]. Rio de Janeiro: IBGE; 2022. [cited 2022 Oct 25]. Available from: https://agenciadenoticias.ibge.gov.br/agencia-noticias/2012-agencia-de-noticias/noticias/34438-populacao-cresce-mas-numero-de-pessoas-com-menos-de-30-anos-cai-5-4-de-2012-a-2021
  » https://agenciadenoticias.ibge.gov.br/agencia-noticias/2012-agencia-de-noticias/noticias/34438-populacao-cresce-mas-numero-de-pessoas-com-menos-de-30-anos-cai-5-4-de-2012-a-2021
• ^10.
  Instituto Brasileiro de Geografia e Estatística. Cor ou raça [Internet]. Rio de Janeiro: IBGE; 2021. [cited 2021 Nov 25]. Available from: https://educa.ibge.gov.br/jovens/conheca-o-brasil/populacao/18319-cor-ou-raca.html
  » https://educa.ibge.gov.br/jovens/conheca-o-brasil/populacao/18319-cor-ou-raca.html
• ^11.
  Instituto Brasileiro de Geografia e Estatística. Educação. Rio de Janeiro: IBGE; 2021. [cited 2021 Nov 25]. Available from: https://educa.ibge.gov.br/jovens/conheca-o-brasil/populacao/18317-educacao.html
  » https://educa.ibge.gov.br/jovens/conheca-o-brasil/populacao/18317-educacao.html
• ^12.
  Nerbass FB, Canzi ER, Araujo R A, et al. Differences in phosphatemia and frequency of consumption of dietary sources of phosphorus in hemodialysis patients in southern and northern Brazil. Brazilian J Nephrol. 2019;41(1):83–8. doi: http://dx.doi.org/10.1590/2175-8239-jbn-2018-0063
  » https://doi.org/10.1590/2175-8239-jbn-2018-0063
• ^13.
  Instituto Brasileiro de Geografia e Estatística. Pesquisa de orçamentos familiares 2017-2018: análise do consumo alimentar pessoal no Brasil. Rio de Janeiro: IBGE; 2020.
• ^14.
  Carvalho AB, Nerbass FB, Cuppari L. Control of hyperphosphatemia and maintenance of calcemia in CKD. Brazilian J Nephrol. 2021;43(4 Suppl 1):632–8. http://dx.doi.org/10.1590/2175-8239-jbn-2021-s105
  » https://doi.org/10.1590/2175-8239-jbn-2021-s105
• ^15.
  Neves PDMM, Sesso RCC, Thomé FS, Lugon JR, Nascimento MM. Brazilian dialysis survey 2019. Brazilian J Nephrol. 2021;43(2):217–27. doi: http://dx.doi.org/10.1590/2175-8239-jbn-2020-0161
  » https://doi.org/10.1590/2175-8239-jbn-2020-0161
• ^16.
  Ikizler TA, Burrowes JD, Byham-Gray LD, Campbell KL, Carrero JJ, Chan W, et al. KDOQI Clinical Practice Guideline for Nutrition in CKD: 2020 Update. Am J Kidney Dis. 2020;76(3, Suppl 1):S1–107. doi: http://dx.doi.org/10.1053/j.ajkd.2020.05.006. PubMed PMID: 32829751.
  » https://doi.org/10.1053/j.ajkd.2020.05.006

Publication Dates

• Publication in this collection
  30 June 2023
• Date of issue
  Oct-Dec 2023

History

• Received
  17 Nov 2022
• Accepted
  10 Apr 2023